-
Final Tests Planned into Potential OPMD Gene Therapy, Could Support Trial in Patients
Benitec Biopharma’s plans 3 tests in a oculopharyngeal muscular dystrophy dog model, final steps to bringing its gene therapy, BB-301, into a Phase 1 trial. Click here to read more about this trial.
What do you think of this study and its findings?
Sorry, there were no replies found.
Log in to reply.